[
    {
        "pregunta": "1. What are the key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA), according to the clinical guidelines?",
        "respuesta": "The provided information does not include specific details about key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA) according to the clinical guidelines. Therefore, I cannot provide a reliable response based on the available data.",
        "contexto": [
            "of pharmacologic intervention addressed in the recommendations are shown in Table 1 Rosters of the Core Leadership Team, Literature Review Team, and both panels are included in Supplementary Appendix 5 ( https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract Guiding principles The development of the recommendations presented herein was guided by the following principles: 1. Consistent with the ACR's 2019 JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>"
        ]
    },
    {
        "pregunta": "2. Why is longer-term glucocorticoid therapy not appropriate in childhood for JIA patients?",
        "respuesta": "Longer-term glucocorticoid therapy is not considered appropriate for patients with juvenile idiopathic arthritis (JIA) during childhood because of its effects on bone health and growth. The recommendations suggest that glucocorticoid therapy should be limited to the lowest effective dose for the shortest duration possible to avoid these adverse effects.",
        "contexto": [
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the treatment of systemic JIA and MAS Glucocorticoids Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. The benefits of glucocorticoids for MAS often outweigh their risks, even in patients whose MAS is triggered by infection. Systemic glucocorticoids may be necessary for severely ill patients because they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term",
            "on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at low doses Tapering and discontinuing bDMARDs is conditionally recommended after inactive disease has been attained in systemic JIA. In children with systemic JIA whose disease is inactive, it may be possible to maintain this inactive disease state with lower doses of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>"
        ]
    },
    {
        "pregunta": "3. What is the recommended approach for shared decision-making when considering treatment options for JIA?",
        "respuesta": "The provided information emphasizes the importance of shared decision-making when considering treatment options for juvenile idiopathic arthritis (JIA). It highlights the necessity of involving families and patients in the decision-making process to ensure that treatment options align with their values, goals, and preferences. Additionally, the guidelines underscore that the recommendations are based on low-quality evidence, which further underscores the importance of clinical judgment and shared decision-making in the everyday care of individuals with JIA.",
        "contexto": [
            "importance of shared decision-making that considers patients' and caregivers' values, goals, and preferences This guideline breaks new ground in recommending treatment withdrawal for children with systemic JIA, who may have lower risks of flare than are associated with other forms of JIA The low quality of evidence supporting these recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of individuals with JIA. Similarly, this guideline and the many uncertainties acknowledged herein represent a powerful reminder of the need for more high-quality evidence to support (or refute) current practices and to improve the management of JIA and well-being of all individuals living with the disease. 23265205, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/art.42037, Wiley Online Library on [12/04/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "of pharmacologic intervention addressed in the recommendations are shown in Table 1 Rosters of the Core Leadership Team, Literature Review Team, and both panels are included in Supplementary Appendix 5 ( https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract Guiding principles The development of the recommendations presented herein was guided by the following principles: 1. Consistent with the ACR's 2019 JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to"
        ]
    },
    {
        "pregunta": "4. What is the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the initial therapy for active oligoarthritis in JIA?",
        "respuesta": "Nonsteroidal anti-inflammatory drugs (NSAIDs) play a role in the initial therapy for active oligoarthritis in juvenile idiopathic arthritis (JIA) as part of a conditionally recommended treatment strategy. They have long been a cornerstone for managing oligoarthritis and are used to ease discomfort. However, the initial trial of NSAIDs should be brief due to potential adverse effects such as gastritis and bruising, as well as limited efficacy unless inactive disease is achieved. There was no consensus among voting panelists on the appropriate duration of initial NSAID use before escalating therapy, and some panelists prefer avoiding their use altogether.",
        "contexto": [
            "joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints involved; guidance for patients with active uveitis, sacroiliitis, or enthesitis can be found in the 2019 guidelines Nonsteroidal antiinflammatory drugs (NSAIDs) A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active oligoarthritis. NSAIDs have long been the cornerstone of treatment for oligoarthritis and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of initial therapy for active oligoarthritis.",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; TMJ = temporomandibular joint.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 4. TMJ arthritis*</h1>",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|NSAIDs are conditionally recommended as initial monotherapy.|Very low|PICO 20. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should non-DMARD treatment (NSAIDs, glucocorticoids) be used as initial therapy?|61–67|\n|Oral glucocorticoids are conditionally recommended against as initial monotherapy.| | | |\n|Conventional synthetic DMARDs are strongly recommended against as initial monotherapy.|Very low|PICO 21. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should DMARD treatment (MTX, calcineurin inhibitor) be used as initial therapy, and is there a preferred order?|67–68|",
            "remain the mainstay of the pharmacologic management of OA, and their use is strongly recommended. A large number of trials have established their short-term efficacy. Oral NSAIDs are the initial oral medication of choice in the treatment of OA, regardless of anatomic location, and are recommended over all other available oral medications. While this guideline did not address the relative merits of different NSAIDs, there is evidence suggesting that certain agents may have more favorable side effect profiles than others Intraarticular glucocorticoid injections are strongly recommended for patients with knee and/or hip OA and conditionally recommended for patients with hand OA. Trials of intraarticular glucocorticoid injections have demonstrated short-term efficacy in knee OA. Intraarticular glucocorticoid injection is conditionally, rather than strongly, recommended for hand OA given the lack of evidence specific to this anatomic location. There are insufficient data to judge the",
            "In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of NSAIDs. The NSAIDs are one of the mainstays of nonoperative treatment for OA and can provide pain relief for patients with mild disease. Oral NSAIDs are, however, associated with adverse events (e.g., peptic ulcer disease, acute kidney injury, increased cardiovascular risk, and bleeding) In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of braces and/or ambulatory aids. This recommendation is conditional because there may be exceptions to this recommendation, and the evidence supporting the recommendation is indirect and very low quality. The exceptions listed for the first recommendation above, including delay for personal reasons or other ongoing medical comorbidities, apply to this recommendation as well. Patients who are recovering from another lower limb surgery (e.g.,"
        ]
    },
    {
        "pregunta": "5. Why are intraarticular glucocorticoids strongly recommended as part of initial therapy for active oligoarthritis in JIA?",
        "respuesta": "Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of the initial therapy for active oligoarthritis in juvenile idiopathic arthritis (JIA) because they have a low potential for adverse effects and a high likelihood of sustained response. Triamcinolone hexacetonide is the preferred agent for these injections, even though the evidence supporting this approach is of low quality. The strong recommendation is based on the favorable risk-benefit profile of intraarticular glucocorticoids in managing symptoms of active oligoarthritis in JIA.",
        "contexto": [
            "altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of initial therapy for active oligoarthritis. Triamcinolone hexacetonide is strongly recommended as the preferred agent. Although the evidence is of low quality, IAGCs are strongly recommended due to low potential of adverse effects and high likelihood of sustained response Oral glucocorticoids are conditionally recommended against as part of initial therapy for active oligoarthritis. If, despite recommendations against, oral glucocorticoids are given to quickly alleviate severe symptoms when an IAGC is not available or feasible, or prior to the onset of action of disease-modifying antirheumatic drugs (DMARDs), treatment should be limited to the lowest effective dose for the shortest duration possible Conventional synthetic DMARDs (csDMARDs) Conventional synthetic DMARDs are strongly recommended if there is an inadequate response to scheduled NSAIDs and/or IAGCs for active",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints involved; guidance for patients with active uveitis, sacroiliitis, or enthesitis can be found in the 2019 guidelines Nonsteroidal antiinflammatory drugs (NSAIDs) A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active oligoarthritis. NSAIDs have long been the cornerstone of treatment for oligoarthritis and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of initial therapy for active oligoarthritis.",
            "remain the mainstay of the pharmacologic management of OA, and their use is strongly recommended. A large number of trials have established their short-term efficacy. Oral NSAIDs are the initial oral medication of choice in the treatment of OA, regardless of anatomic location, and are recommended over all other available oral medications. While this guideline did not address the relative merits of different NSAIDs, there is evidence suggesting that certain agents may have more favorable side effect profiles than others Intraarticular glucocorticoid injections are strongly recommended for patients with knee and/or hip OA and conditionally recommended for patients with hand OA. Trials of intraarticular glucocorticoid injections have demonstrated short-term efficacy in knee OA. Intraarticular glucocorticoid injection is conditionally, rather than strongly, recommended for hand OA given the lack of evidence specific to this anatomic location. There are insufficient data to judge the",
            "rather than strongly, recommended for hand OA given the lack of evidence specific to this anatomic location. There are insufficient data to judge the choice of shortacting over long-acting preparations or the use of low rather than high doses. A recent report 2 Ultrasound guidance for intraarticular glucocorticoid injection is strongly recommended for injection into hip joints. When available, ultrasound guidance for steroid injection may help ensure accurate drug delivery into the joint, but is not required for knee and hand joints. However, imaging guidance for injection into hip joints is strongly recommended. Intraarticular glucocorticoid injections versus other injections are conditionally recommended for patients with knee, hip, and/or hand OA. In OA generally, intraarticular glucocorticoid injection is conditionally recommended over other forms of intraarticular injection, including hyaluronic acid preparations. Head-to-head comparisons are few, but the evidence for efficacy of"
        ]
    },
    {
        "pregunta": "6. Which conventional synthetic DMARD is conditionally recommended as a preferred agent for JIA patients with inadequate response to NSAIDs and/or intraarticular glucocorticoids?",
        "respuesta": "Methotrexate is the conventional synthetic disease-modifying antirheumatic drug (DMARD) that is conditionally recommended as a preferred agent for juvenile idiopathic arthritis (JIA) patients with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intraarticular glucocorticoids.",
        "contexto": [
            "|Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs.|Very low|PICO 15. In children with JIA with active TMJ arthritis, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous and oral), LEF, SSZ, and/or HCQ?|58–59|\n|MTX is conditionally recommended as a preferred agent over LEF.| | | |\n|Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 16. In children with JIA with active TMJ arthritis, should systemic biologic therapies be recommended, and should there be any preferred order of treatment: TNFi, biologic treatments with other mechanisms of action?|59|\n|There is no preferred biologic agent.| | | |",
            "to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            "(csDMARDs) Conventional synthetic DMARDs are strongly recommended if there is an inadequate response to scheduled NSAIDs and/or IAGCs for active oligoarthritis. Methotrexate is conditionally recommended as a preferred agent over leflunomide, sulfasalazine, or hydroxychloroquine (in that order). Despite an absence of comparator trials, methotrexate is the preferred agent, given the preponderance of evidence showing its long-term safety and efficacy in children With regard to the route of administration of methotrexate, the 2019 JIA guidelines conditionally recommended subcutaneous over oral administration for polyarthritis . This recommendation was conditional because the supporting evidence was of very low quality and patient preferences may guide choice of route of administration. There is little reason to suggest that methotrexate should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>"
        ]
    },
    {
        "pregunta": "7. What is the rationale behind the preference for subcutaneous over oral administration of methotrexate in JIA patients with polyarticular arthritis?",
        "respuesta": "The rationale behind the preference for subcutaneous over oral administration of methotrexate in juvenile idiopathic arthritis (JIA) patients with polyarticular arthritis is supported by the 2019 JIA guidelines. The guidelines conditionally recommend subcutaneous administration over oral administration because, despite the very low quality of supporting evidence, it suggests potential benefits in terms of efficacy for polyarticular conditions. Additionally, this recommendation is conditional since patient preferences and experiences may guide the route of administration choice. The preference for subcutaneous administration is based on recommendations that aim to maximize the use of methotrexate before considering switching or adding other DMARDs.",
        "contexto": [
            "(csDMARDs) Conventional synthetic DMARDs are strongly recommended if there is an inadequate response to scheduled NSAIDs and/or IAGCs for active oligoarthritis. Methotrexate is conditionally recommended as a preferred agent over leflunomide, sulfasalazine, or hydroxychloroquine (in that order). Despite an absence of comparator trials, methotrexate is the preferred agent, given the preponderance of evidence showing its long-term safety and efficacy in children With regard to the route of administration of methotrexate, the 2019 JIA guidelines conditionally recommended subcutaneous over oral administration for polyarthritis . This recommendation was conditional because the supporting evidence was of very low quality and patient preferences may guide choice of route of administration. There is little reason to suggest that methotrexate should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is",
            "to the subcutaneous route of administration, and increased doses of folic/folinic acid are the preferred initial strategies over switching to another DMARD because of the efficacy, long-term safety, and low costs associated with methotrexate. The recommendation is conditional because patient preferences play an important role in the decision whether to continue methotrexate or switch to other DMARDs. Switching to subcutaneous methotrexate is conditionally recommended over the addition of/ switching to alternative DMARD(s) for patients taking oral methotrexate who are not at target This recommendation is consistent with the voting panel's overarching principle of maximizing use of methotrexate prior to switching/adding DMARDs. However, there are no data comparing outcomes in patients who switch to subcutaneous methotrexate versus another treatment strategy that includes other DMARDs. The recommendation is conditional because patient preferences and the magnitude of previous response to",
            "|Switching to subcutaneous methotrexate is conditionally recommended over the addition of/switching to alternative DMARD(s) for patients taking oral methotrexate who are not at target.|Very low|PICO 18|p. 235|</p>",
            "recommended over the combination of methotrexate plus a bDMARD or tsDMARD The recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of ≥1 csDMARD will prefer combination treatment for a more rapid response. Recommendations for administration of methotrexate (Table 3) Oral methotrexate is conditionally recommended over subcutaneous methotrexate for patients initiating methotrexate Oral administration is preferred, despite moderate evidence suggesting superior efficacy of subcutaneous injections, due to the ease of oral administration and similar bioavailability at typical starting doses Initiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/ titration to a weekly dose of <15 mg The recommendation is conditional because there are few studies comparing different dosing strategies and wide variation in physician and",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Evidence table(s), in Supp. App. 2|\n|---|---|---|---|\n|Oral methotrexate is conditionally recommended over subcutaneous methotrexate for patients initiating methotrexate.|Moderate|PICO 9|p. 181|\n|Initiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/titration to a weekly dose of &lt;15 mg.|Moderate/very low‡|PICO 10.C1–C3|p. 184–5|\n|A split dose of oral methotrexate over 24 hours or subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.|Very low|PICO 16 and PICO 15|p. 206–10|"
        ]
    },
    {
        "pregunta": "8. When should biologic DMARDs be strongly recommended for JIA patients with inadequate response to NSAIDs and/or conventional synthetic DMARDs?",
        "respuesta": "Biologic DMARDs are strongly recommended for juvenile idiopathic arthritis (JIA) patients with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intraarticular glucocorticoids, as well as at least one conventional synthetic DMARD. There is no preferred biologic agent specified in the guidelines for such cases.",
        "contexto": [
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "|Biologic DMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy.|Very low|PICO 22. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should biologic treatment (anakinra, canakinumab, tocilizumab, or others) be used as initial therapy, and is there a preferred order?|69–71|\n|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "|Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs.|Very low|PICO 15. In children with JIA with active TMJ arthritis, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous and oral), LEF, SSZ, and/or HCQ?|58–59|\n|MTX is conditionally recommended as a preferred agent over LEF.| | | |\n|Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 16. In children with JIA with active TMJ arthritis, should systemic biologic therapies be recommended, and should there be any preferred order of treatment: TNFi, biologic treatments with other mechanisms of action?|59|\n|There is no preferred biologic agent.| | | |",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>",
            "|Conventional synthetic DMARDs are strongly recommended if there is inadequate response to scheduled NSAIDs and/or IAGCs. MTX is conditionally recommended as a preferred agent over LEF, SSZ, and HCQ (in that order).|Low (MTX); Very low (LEF, SSZ, HCQ)|PICO 5. In children with oligoarticular JIA, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous or oral), LEF, SSZ, and/or HCQ?|28–41|\n|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |"
        ]
    },
    {
        "pregunta": "9. Why is formal assessment of disease activity using validated measures conditionally recommended for JIA patients?",
        "respuesta": "Formal assessment of disease activity using validated measures is conditionally recommended for juvenile idiopathic arthritis (JIA) patients to guide treatment decisions, particularly to facilitate treat-to-target approaches. This recommendation is supported by very low-quality evidence and aims to ensure that treatment is appropriately adjusted based on disease activity, thereby improving patient outcomes.",
        "contexto": [
            "symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches. Treatment for oligoarthritis can and should be modified based on the involvement of specific joints or disease features Voting panelists conditionally recommended formal assessment of disease activity using validated measures. There are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "and small joint surgeries are not frequently a part of the current management of rheumatoid arthritis. Disease activity and disease activity levels refer to those calculated using an ACR-endorsed rheumatoid arthritis disease activity measure * ACR = American College of Rheumatology. individuals with RA. Aerobic, resistance, aquatic, and mind-body exercise were considered together in the evidence supporting this recommendation. The exercise type, frequency, intensity, and duration were not formally defined because the evidence on exercise interventions did not support such precision in the recommendation, and there is considerable variation in patient values, preferences, and access to different types of exercise. The specific elements of an exercise intervention should be tailored to each person at the given time in their disease trajectory, considering their capabilities, access, and other health conditions. National physical activity guidelines can aid such instruction . We"
        ]
    },
    {
        "pregunta": "10. What is the recommended initial therapy for systemic JIA without macrophage activation syndrome (MAS) according to the guidelines?",
        "respuesta": "The recommended initial therapy for systemic juvenile idiopathic arthritis (JIA) without macrophage activation syndrome (MAS) according to the guidelines is the use of biologic DMARDs. Specifically, IL-1 and IL-6 inhibitors are conditionally recommended as initial monotherapy for systemic JIA without MAS. No specific preferred agent is endorsed, and some panelists preferred starting treatment with a short-acting agent such as anakinra.",
        "contexto": [
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 6. Systemic JIA with MAS*</h1>",
            "switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed regarding a highly fatal lung disease observed in some children with systemic JIA, most of whom were treated with bDMARDs. Observed risk factors include younger age with MAS, a history of reactions to tocilizumab, and trisomy 21 NSAIDs NSAIDs are conditionally recommended as initial monotherapy for systemic JIA without MAS. Studies suggest that a small proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>"
        ]
    }
]